A wide range of applications in biopharmaceutical industry, increasing biological products pipeline, increasing use and development of newer technologies for drug purification are expected to drive the growth of protein A resins market over forecast period. Furthermore, advantages over conventional chromatographic separation of antibodies such as high selectivity, improved antibody yield along with ease in large and small scale antibody purification may further drive protein a resins market. However, high-cost of Protein A resin purification method in comparison with conventional chromatographic separation techniques hindering the protein A resin market growth. In addition, development of alternatives for protein A resins such as aqueous two phase separation, mixed mode chromatography and cation exchange may hamper the protein A resins market during forecast period.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-protein-a-resin-market/#ulp-4H8Z4LpNMLEuOnnx

Protein A resin market has been segmented on the basis of application, end user and matrix type

Based on matrix type, protein A resin market is segmented into
Glass or Silica
Agarose
Organic Polymer

Based on application, protein A resin market is segmented into
Antibody separation
Immunoprecipitation

Based on end-user, protein A resin market is segmented into
Biopharmaceutical industries
Clinical Research Laboratories
Academic Institutions

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-protein-a-resin-market/#ulp-c654SbFYO64MsOhu

Companies in Protein A Resin market are investing in research and development to gain the competitive advantage. Geographic expansion, new product development and collaborations are major strategies adopted by the key market players. For instance, In February 2016, German life sciences company Atoll acquired by Repligen for $22.5 Mn. This acquisition will expand Repligens chromatography column business and further diversifying its business supply of protein A ligands. Similarly, in February 2016, Repligen Corporation has extended a long term supply agreement with GE Healthcare through 2019 for Protein A ligands manufacturing at its facility in Lund, Sweden. Furthermore, in 2011, Novasep, a leading supplier of manufacturing solutions to the life sciences industries, launched of AbSolute High Cap, a new generation Protein A media, based on modified silica.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-protein-a-resin-market/#ulp-14mlyhjMGhVjZqa3

Geographically protein a resin market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the market revenue share among the all regions due to technological advancements, well-established healthcare industry and favourable government policies. In addition, growth of monoclonal antibodies market in U.S. directly contributing to growth of effective antibody purifying techniques and related products & services. Protein A resin market is expected to grow at significant rate in Asia – Pacific region due to shifting the global interest for manufacturing in biopharmaceutical manufacturing capacities in emerging economies of the region like India and China. Europe’s growth in monoclonal antibodies sales may drive the revenue growth of protein A resin market in the region.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-protein-a-resin-market/

Some of the players in protein A resin market are Novasep Holding SAS (Novasep) (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), E. Merck KG (Merck KGaA) (Germany), JSR Corporation (Japan), Tosoh Corporation (Japan), Repligen Corporation (U.S.), Expedeon Ltd. (U.S.), and GenScript (U.S.) to name a few.